AstraZeneca Investor Day Presentation Deck
Conclusions
In the first randomised Phase III trial in breast cancer, T-DXd demonstrated:
17
Highly clinically meaningful and statistically significant improvement in PFS compared with T-DM1 in patients
with HER2-positive mBC
PFS HR of 0.28 (P = 7.8 x 10-22)
• Consistent benefit seen across key subgroups and efficacy endpoints, with a confirmed ORR for T-DXd of 79.7% vs 34.2%
for T-DM1 (CR, 16.1% vs 8.7%)
●
Encouraging OS trend at the time of first interim analysis
12-month OS rate for T-DXd was 94.1% vs 85.9% for T-DM1
A safety profile that is comparable between the two arms
Similar rates of all grade and grade 23 drug-related TEAEs between arms
• There were no grade 4 or 5 ILD/pneumonitis events in either arm
●
These data support T-DXd becoming the standard of care for 2L HER2-positive mBC
mBC, metastatic breast cancer.View entire presentation